BR112018068996A2 - derivados de triterpeno, compostos intermediários e composições farmacêuticas - Google Patents
derivados de triterpeno, compostos intermediários e composições farmacêuticasInfo
- Publication number
- BR112018068996A2 BR112018068996A2 BR112018068996A BR112018068996A BR112018068996A2 BR 112018068996 A2 BR112018068996 A2 BR 112018068996A2 BR 112018068996 A BR112018068996 A BR 112018068996A BR 112018068996 A BR112018068996 A BR 112018068996A BR 112018068996 A2 BR112018068996 A2 BR 112018068996A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- triterpenoid
- hif
- activation
- vitro
- Prior art date
Links
- 150000003648 triterpenes Chemical class 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000004913 activation Effects 0.000 abstract 3
- 208000014674 injury Diseases 0.000 abstract 3
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 abstract 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 abstract 1
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 206010008129 cerebral palsy Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000037353 metabolic pathway Effects 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000008736 traumatic injury Effects 0.000 abstract 1
- 210000005167 vascular cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16193684 | 2016-10-13 | ||
| PCT/EP2017/075042 WO2018069086A1 (en) | 2016-10-13 | 2017-10-03 | Hydroxamate triterpenoid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018068996A2 true BR112018068996A2 (pt) | 2019-01-22 |
Family
ID=57136723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018068996A BR112018068996A2 (pt) | 2016-10-13 | 2017-10-03 | derivados de triterpeno, compostos intermediários e composições farmacêuticas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10766855B2 (https=) |
| EP (1) | EP3365351B1 (https=) |
| JP (1) | JP6598224B2 (https=) |
| KR (1) | KR102038930B1 (https=) |
| CN (1) | CN108368150B (https=) |
| AU (1) | AU2017341257B2 (https=) |
| BR (1) | BR112018068996A2 (https=) |
| CA (1) | CA3020387C (https=) |
| ES (1) | ES2774198T3 (https=) |
| HK (1) | HK1254200A1 (https=) |
| IL (1) | IL259391B (https=) |
| MX (2) | MX364919B (https=) |
| RU (1) | RU2018136782A (https=) |
| WO (1) | WO2018069086A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020157494A1 (en) * | 2019-01-30 | 2020-08-06 | Rothamsted Research Ltd | Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy |
| CN114805469A (zh) * | 2021-01-27 | 2022-07-29 | 中国科学院上海药物研究所 | 含吡唑的白桦脂酸类衍生物，其制备方法及用途 |
| CN117567544A (zh) * | 2021-04-27 | 2024-02-20 | 中国医学科学院药物研究所 | 一类具有α,β-不饱和酮结构五环三萜类化合物在预防和治疗神经退行性疾病中的用途 |
| WO2024145502A1 (en) * | 2022-12-29 | 2024-07-04 | The Board Of Regents Of The University Of Texas System | Synthetic triterpenoids and compositions thereof in weight management, skeletal muscle function, and appetite suppression |
| CN119504913B (zh) * | 2024-11-18 | 2025-09-26 | 南京中医药大学 | 一类五环三萜衍生物及其医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002322068A (ja) * | 2001-02-26 | 2002-11-08 | Japan Science & Technology Corp | 血管再生促進剤 |
| KR100821649B1 (ko) * | 2006-01-24 | 2008-04-11 | 서울시립대학교 산학협력단 | 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제 |
| CN101367861A (zh) * | 2007-08-15 | 2009-02-18 | 中国药科大学 | 2-羟基-3-脱氧五环三萜类化合物及其衍生物、其制备方法及用途 |
| PL2252283T3 (pl) * | 2008-01-11 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby |
| WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| US20100144688A1 (en) * | 2008-12-10 | 2010-06-10 | Advanced Life Sciences, Inc. | 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids |
| KR101811462B1 (ko) * | 2010-01-11 | 2018-01-25 | 피닉스 바이오테크놀러지 인코포레이티드. | 협죽도 추출물을 포함하는 신경질환 치료용 조성물 |
| CN102180939B (zh) | 2011-03-30 | 2013-02-20 | 沈阳化工大学 | 一种抗肿瘤活性的熊果酸化学修饰物及其制备方法 |
| US8324264B1 (en) * | 2011-07-22 | 2012-12-04 | Sequoia Sciences, Inc. | Inhibitors of bacterial biofilms and related methods |
| CN102499925B (zh) * | 2011-10-21 | 2015-11-11 | 上海中医药大学 | 一种中性粒细胞弹性蛋白酶抑制剂 |
-
2017
- 2017-10-03 EP EP17790966.0A patent/EP3365351B1/en active Active
- 2017-10-03 WO PCT/EP2017/075042 patent/WO2018069086A1/en not_active Ceased
- 2017-10-03 US US16/099,800 patent/US10766855B2/en active Active
- 2017-10-03 KR KR1020187028923A patent/KR102038930B1/ko not_active Expired - Fee Related
- 2017-10-03 CN CN201780004882.0A patent/CN108368150B/zh not_active Expired - Fee Related
- 2017-10-03 CA CA3020387A patent/CA3020387C/en active Active
- 2017-10-03 MX MX2018006429A patent/MX364919B/es active IP Right Grant
- 2017-10-03 BR BR112018068996A patent/BR112018068996A2/pt not_active Application Discontinuation
- 2017-10-03 ES ES17790966T patent/ES2774198T3/es active Active
- 2017-10-03 JP JP2018524188A patent/JP6598224B2/ja active Active
- 2017-10-03 HK HK18113340.0A patent/HK1254200A1/zh unknown
- 2017-10-03 AU AU2017341257A patent/AU2017341257B2/en active Active
- 2017-10-03 RU RU2018136782A patent/RU2018136782A/ru not_active Application Discontinuation
-
2018
- 2018-05-15 IL IL25939118A patent/IL259391B/en active IP Right Grant
- 2018-05-24 MX MX2019005448A patent/MX2019005448A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102038930B1 (ko) | 2019-11-05 |
| AU2017341257A1 (en) | 2018-11-01 |
| AU2017341257B2 (en) | 2019-08-08 |
| IL259391A (en) | 2018-07-31 |
| MX2019005448A (es) | 2019-07-04 |
| CN108368150A (zh) | 2018-08-03 |
| RU2018136782A (ru) | 2020-04-20 |
| US10766855B2 (en) | 2020-09-08 |
| WO2018069086A1 (en) | 2018-04-19 |
| MX2018006429A (es) | 2018-09-27 |
| CA3020387C (en) | 2020-07-28 |
| IL259391B (en) | 2019-10-31 |
| RU2018136782A3 (https=) | 2020-04-20 |
| KR20180117700A (ko) | 2018-10-29 |
| ES2774198T3 (es) | 2020-07-17 |
| EP3365351B1 (en) | 2019-12-04 |
| EP3365351A1 (en) | 2018-08-29 |
| CN108368150B (zh) | 2022-02-25 |
| US20190367447A1 (en) | 2019-12-05 |
| CA3020387A1 (en) | 2018-04-19 |
| JP6598224B2 (ja) | 2019-10-30 |
| MX364919B (es) | 2019-05-13 |
| JP2019519464A (ja) | 2019-07-11 |
| HK1254200A1 (zh) | 2019-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068996A2 (pt) | derivados de triterpeno, compostos intermediários e composições farmacêuticas | |
| Huang et al. | The complexity of the Nrf2 pathway: beyond the antioxidant response | |
| Singh et al. | Flavones: An important scaffold for medicinal chemistry | |
| Al Marzouqi et al. | Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts | |
| Gu et al. | (−)-Oleocanthal exerts anti-melanoma activities and inhibits STAT3 signaling pathway | |
| Choi et al. | Methanol extract of Sanguisorba officinalis L. with cytotoxic activity against PC3 human prostate cancer cells | |
| MX2021014938A (es) | Inhibidores de aldosa reductasa y metodos de uso. | |
| BR112016026809A2 (pt) | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| Orlikova et al. | Styryl-lactone goniothalamin inhibits TNF-α-induced NF-κB activation | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| CN107406464A8 (zh) | 精氨酸酶抑制剂及其治疗用途 | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| HK1217944A1 (zh) | 醛糖還原酶抑制劑和其用途 | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| Yang et al. | Inhibitory effects of juglanin on cellular senescence in human dermal fibroblasts | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| BR112017010592A2 (pt) | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína | |
| PH12022552773A1 (en) | Tetrahydroisoquinoline compounds as nrf2 activators | |
| BR112022003745A2 (pt) | Proteínas de fusão terapêuticas | |
| BR112016030730A8 (pt) | composto | |
| BR112017012588A2 (pt) | compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta) | |
| BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
| MX2021006527A (es) | Compuesto macrociclico y su uso. | |
| BR112017027762A2 (pt) | compostos de c,o-espiro aril glicosídeo, preparação para os mesmos e uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |